This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Amdipharm Mercury Company Limited

No. 1 Croydon, 12 - 16 Addiscombe Road, Croydon, Surrey, CR0 0XT, UK
Telephone: +44 (0)208 588 9100
Fax: +44 (0)208 686 0807
WWW: http://www.amcolimited.com
Medical Information Direct Line: 08700 70 30 33
Medical Information e-mail: medicalinformation@amcolimited.com
Customer Care direct line: +44 (0)208 588 9273
Medical Information Fax: +44 (0)208 686 0807

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 18/11/2013
SPC Traxam Gel (POM) and Traxam Pain Relief Gel (P)


Go to top of the page
1. Name of the medicinal product

Traxam 3% w/w Gel

Traxam Pain Relief 3% w/w Gel

Felbinac 3% w/w Gel


Go to top of the page
2. Qualitative and quantitative composition

Active Ingredient:

Felbinac (Biphenylacetic Acid) 3% w/w


Go to top of the page
3. Pharmaceutical form

A clear non-greasy, non-staining gel containing 30mg felbinac in each gram.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Prescription Only Medicine

This medicine is a topical anti-inflammatory and analgesic. It is indicated for the relief of rheumatic pain, pain of non-serious arthritic conditions and soft tissue injuries such as sprains, strains and contusions.

This medicine may be used as a coupling agent for ultrasound where both treatments are indicated.

Pharmacy Only Medicine

This medicine is a topical anti-inflammatory and analgesic. It is indicated for the relief of rheumatic pain, pain of non-serious arthritic conditions and soft tissue injuries such as sprains, strains and contusions.


Go to top of the page
4.2 Posology and method of administration

Prescription Only Medicine

Rub 1g of this medicine (approximately 1 inch (2.5cm) of gel) into the affected area(s) 2 to 4 times a day. If symptoms do not resolve within 14 days, the patient should be reviewed.

The total daily dose should not exceed 25g per day irrespective of the number of affected areas.

Elderly: No special dosage recommendations are made for elderly patients.

Children: Safe use of this medicine in early childhood has not been established.

Hands should be washed following application of this medicine unless they are the treatment site.

Pharmacy Medicine

Rub 1g of this medicine (approximately 1 inch (2.5cm) of gel) into the affected area(s) 2 to 4 times a day. Do not use for longer than 7 days.

The total daily dose should not exceed 25g per day regardless of the number of affected areas.

Elderly: No special dosage recommendations are made for elderly patients.

Children: Not recommended for use in children under 12 years of age.

Hands should be washed following application of this medicine unless they are the treatment site.


Go to top of the page
4.3 Contraindications

Prescription Only Medicine

Hypersensitivity to the ingredients. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory drugs.

Pharmacy Medicine

Hypersensitivity to the ingredients. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory drugs. Children under 12 years of age.


Go to top of the page
4.4 Special warnings and precautions for use

Use of this medicine should be limited to intact and non-diseased skin. Contact with mucous membranes and the eyes should be avoided.

Discontinue if rash develops.

This medicine gel should not be applied with occlusive dressings at the same site as other topical preparations.

Topical application of large amounts may result in systemic effects, such as hypersensitivity, asthma and renal disease.

To avoid the possibility of photosensitivity, patients should be advised against excessive exposure to sunlight of treated areas.

Safe use of this medicine in early childhood has not been established.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Felbinac is highly protein bound. However, serum levels following topical application are extremely low and therefore clinical drug interactions are unlikely.

Concurrent use of aspirin or other NSAIDs may result in an increased incidence of adverse reactions.


Go to top of the page
4.6 Pregnancy and lactation

Since the safety of felbinac in human pregnancy and lactation has not been established, its use in these circumstances is not recommended. As with other non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis, dystocia and delayed parturition were observed when felbinac was administered simultaneously in animal studies.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

The overall incidence of side effects reported with this medicine is low (less than 2%). Local effects such as mild erythema, irritation, dermatitis, pruritis and paraesthesia, which recover spontaneously upon cessation of treatment are the most common reactions.

Anaphylaxis; respiratory reactivity comprising asthma, aggravated asthma or dyspnoea; purpura; angioedema; bullous dermatoses (including epidermal necrolysis and erythema multiforme) and skin photosensitivity have been reported.

Systemic side effects are rare; gastrointestinal disturbances and hypersensitivity reactions such as widespread rashes (including urticaria) and bronchospasm have been reported with felbinac.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


Go to top of the page
4.9 Overdose

If accidentally ingested, treatment should be symptomatic and supportive. Correction of severe electrolyte abnormalities should be considered.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Felbinac is an anti-inflammatory/analgesic agent which has been developed into a topical gel for local treatment and pain and inflammation associated with conditions of the musculo-skeletal system.


Go to top of the page
5.2 Pharmacokinetic properties

Clinical pharmacokinetic studies show that a topical dose of 10g of this medicine results in low circulating levels of felbinac in serum (600ng/ml). This is more than 20 times less than the levels recorded following oral administration of a single dose of 600mg fenbufen.

Results of distribution studies demonstrate that felbinac is transferred preferentially to a site of inflammation when applied topically.

The metabolism of felbinac is consistent with the known metabolic profile of fenbufen.


Go to top of the page
5.3 Preclinical safety data

Testing of biphenylacetic acid includes single and repeat dose studies, foetal toxicity and fertility studies, mutagenic and carcinogenic potential studies which show an acceptable toxicity profile for the active ingredient.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Carboxyvinyl Polymer

Diisopropanolamine

Ethanol (96%) BP

Purified Water BP


Go to top of the page
6.2 Incompatibilities

None.


Go to top of the page
6.3 Shelf life

1. Fluorovinyl resin-coated blind ended Aluminium Tubes with a plastic cap:

36 months

2. LDPE/Aluminium Foil/LDPE laminate tubes with a plastic cap:

24 months

3. Polyamide-imide or epoxyphenolic coated blind ended aluminium tubes with a plastic cap:

36 months


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

This medicine is packed in fluorovinyl resin-coated blind ended Aluminium Tubes with a plastic cap, LDPE/Aluminium Foil/LDPE laminate tubes with a plastic cap or Polyamide-imide or epoxyphenolic coated blind ended aluminium tubes with a plastic cap.

Pack sizes: 7.5g, 25g, 30g (Pharmacy)

Pack sizes: 50g, 100g (Prescription Only)


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. Marketing authorisation holder

Mercury Pharmaceuticals Ltd

No. 1 Croydon,

12-16 Addiscombe Road,

Croydon CR0 0XT, UK


Go to top of the page
8. Marketing authorisation number(s)

PL 12762/0085


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

31/03/2009


Go to top of the page
10. Date of revision of the text

November 2013



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/22519/SPC/


Active Ingredients/Generics